EODData

LSE, 0RGI: Cosmo NV Ord Shs

20 Nov 2026
LAST:

53.10

CHANGE:
 1.30
OPEN:
54.60
HIGH:
54.60
ASK:
0.00
VOLUME:
483
CHG(%):
2.39
PREV:
54.40
LOW:
53.10
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
20 Nov 2654.6054.6053.1053.10483
19 Nov 2656.4056.4054.4054.40120
18 Nov 2657.3057.4055.7055.70935
17 Nov 2657.3057.6056.2056.501.5K
16 Nov 2659.2059.9058.7058.70790
13 Nov 2658.3058.8057.2057.30392
12 Nov 2658.3059.6057.4058.55299
11 Nov 2657.6057.9057.0057.40792
10 Nov 2659.8059.8057.1557.302.2K
09 Nov 2656.8059.7056.3058.80852

PROFILE

Name:Cosmo NV Ord Shs
About:Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Address:Riverside II, Dublin, Ireland, 2
Website:https://www.cosmopharma.com
ISIN:NL0011832936
LEI:724500OX0EBQRYTVV639

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:43.91 
Price to Sales:8.47 
Price to Book:1.88 
Profit Margin:-0.06 
Operating Margin:-0.11 
Return on Assets:-0.01 
Return on Equity:-0.01 
EPS Ratio:1.31 
DivYield:0.03 
Div/Share:2.05 
Revenue:94.96M 
EBITDA:1.11M 
Shares:15.0M 
Market Cap:796.61M 

TECHNICAL INDICATORS

MA5:55.684.9%
MA10:56.786.9%
MA20:56.656.7%
MA50:54.773.1%
MA100:57.558.4%
MA200:71.4034.5%
RSI14:45.11
WPR14:-100.00 
MTM14:-4.10
ROC14:-0.07 
ATR:2.35 
Week High:59.9012.8%
Week Low:53.100.0%
Month High:61.1015.1%
Month Low:51.5034.5%
Year High:129.60144.1%
Year Low:49.207.9%
Volatility:24.59 

RECENT DIVIDENDS

Date Amount
04 Jun 2025$1.77
10 Jul 2024$1.79
31 May 2023$0.94
01 Jun 2022$0.90
29 May 2017$1.51
01 Sep 2016$0.02
17 May 2016$0.02